OCAT
Vuelve a respirarse optimismo en el foro:
-En el último mes los institucionales han pasado de 15.000 acciones a 355.000.
-El lunes que viene estará en la Jefferies 2015 Global Healthcare Conference.
-Por otra parte, GE Healthcare se ha pillado un local de 20000 metros cuadrados que se especula que podría tener que ver con la fabricación de nuestras plaquetas.
http://www.telegram.com/article/20140821/NEWS/308219923
-De hecho, GE Healthcare es la patrocinadora del 10º congreso anual de células y medicina regenerativa donde durante los próximos 3 días va a tratar la comercialización de los tratamientos de células y donde han invitado al CEO de OCAT va a dar una charla, mañana a las 14 h:
"LRMN & GE Healthcare
The May 2015 meeting of the LRMN is focused on the topic of cell therapy commercialisation, with three CEO's from east and west coast US cell therapy companies presenting an update on their company pipelines and providing us with insight into their experiences in our sector.
This meeting is kindly supported by GE Healthcare Life Sciences and is FREE OF CHARGE to attend. GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Their expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest."
Conferencia:
Developing a scalable process for manufacturing dendritic cells
• How Ocata Therapeutics developed their highly scalable process which involves a readily renewable stem cell source as the starting material
• The importance of a strong IP position around core cell therapy components when scaling up manufacturing processes
• What clinical opportunities become a possibility with a scalable process for manufacturing dendritic cells?
Dr. Paul Wotton, President & Chief Executive Officer, Ocata Therapeutics
«Después de nada, o después de todo/ supe que todo no era más que nada.»